1,120
Participants
Start Date
November 16, 2020
Primary Completion Date
January 31, 2021
Study Completion Date
February 16, 2021
Hydroxychloroquine
Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
Favipiravir
Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
Favipiravir + Hydroxychloroquine
Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Placebo
Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Ankara City Hospital, Ankara
Başakşehir Çam ve Sakura City Hospital, Istanbul
Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul
Istanbul University Istanbul Medicine Faculty, Istanbul
Kartal Dr. Lütfi Kırdar City Hospital, Istanbul
Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul
Health Institutes of Turkey
OTHER_GOV